All In Biotech

Drug Trial Radar · NCT07800897

A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Participants

A Phase 1, Open-label, Randomized, Pharmacokinetic Study to Assess the Drug Interactions and Food Effect of Navlimetostat (BMS-986504) in Healthy Female Participants

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Aug 31, 2026

Primary completion

Mar 25, 2027

Study completion Mar 25, 2027

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Sep 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the food effect and drug interactions on drug levels of Navlimetostat in health adult female participants

Conditions

  • Healthy Female Adults

Interventions

  • NavlimetostatDrug

    Specified dose on specified days

  • ItraconazoleDrug

    Specified dose on specified days

  • RifampinDrug

    Specified dose on specified days

  • MidazolamDrug

    Specified dose on specified days

  • PantoprazoleDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed concentration (Cmax) of NavlimetostatTime frame: Up to approximately 3 weeks
  2. Area under the concentration-time curve from time zero to 192 hours (AUC(0-192)) of NavlimetostatTime frame: Up to approximately 3 weeks
  3. (AUC(INF)) of Navlimetostat with the coadministration of itraconazoleTime frame: Up to approximately 3 weeks
  4. AUC(INF) of Navlimetostat without the coadministration of itraconazoleTime frame: Up to approximately 3 weeks
  5. Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of NavlimetostatTime frame: Up to approximately 3 weeks
  6. AUC(INF) of Navlimetostat with the coadministration of RifampinTime frame: Up to approximately 3 weeks
  7. AUC(INF) of Navlimetostat without the coadministration of RifampinTime frame: Up to approximately 3 weeks
  8. Cmax of MidazolamTime frame: Up to approximately 3 weeks
  9. AUC(0-T) of MidazolamTime frame: Up to approximately 3 weeks
  10. AUC(INF) of Midazolam with the coadministration of NavlimetostatTime frame: Up to approximately 3 weeks
  11. AUC(INF) of Midazolam without the coadministration of NavlimetostatTime frame: Up to approximately 3 weeks
  12. AUC(INF) of Navlimetostat with a high fat mealTime frame: Up to approximately 3 weeks
  13. AUC(INF) of Navlimetostat without a high fat mealTime frame: Up to approximately 3 weeks
  14. AUC(INF) of Navlimetostat with the coadministration of PantoprazoleTime frame: Up to approximately 3 weeks
  15. AUC(INF) of Navlimetostat without the coadministration of PantoprazoleTime frame: Up to approximately 3 weeks
  16. Drug-related AEsTime frame: Up to approximately 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Syneos Health Clinique; Inc.

    Québec, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.